AmideBio has leveraged its core manufacturing technology to pursue a series of therapeutic targets that include, ultrastable insulin, glucose sensing insulin and solution stable glucagon. In the diabetes space, a library of single chain insulin (SCI) analogs have been manufactured using a proprietary design protocol optimized for the production of SCI analogs that are resistant to thermal and chemical degradation at elevated temperature while maintaining maximal bioactivity. These novel insulins can address a number of stability issues that limit the growth of existing insulin as a therapy for worldwide markets, including breaking the cold chain, oral delivery, and improvements in insulin pump operation, patches, and increased concentrations above U1000. Similarly, the company has designed and manufactured a library of solution stable glucagon analogues suitable for use in a pump for either an artificial pancreas or for the treatment of cholesterol hyperinsulinism, a rare disease. The company has also recently begun a discovery program for novel forms of glucose sensing insulins that will eliminate the need for both basal and prandial insulins.
Additional therapeutic opportunities being pursued by AmideBio include BioSimilars and BioBetters such as GLP-1 analogs, as well as novel peptides to treat orphan diseases.